Taking into account the chemoresistance to taxanes including docetaxel and paclitaxel, patients from an immunohistochemical study who had low expression of class III beta-tubulin isotype in non-small cell lung cancer showed a better response rate, longer progression-free survival, and longer overall survival when treated with paclitaxel [26]. This evidence concerns the gene TUBB and non-small cell lung carcinoma.